Current Appointments & Affiliations
Professor of Neurosurgery
·
2021 - Present
Neurosurgery, Neuro-Oncology,
Neurosurgery
Professor in Neurology
·
2021 - Present
Neurology, General & Community Neurology,
Neurology
Member of the Duke Cancer Institute
·
2003 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.
Journal Article Nat Commun · August 11, 2024 Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccin ... Full text Link to item CiteUse, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.
Journal Article Neurooncol Pract · April 2024 BACKGROUND: Isocitrate dehydrogenase (IDH) is commonly mutated (mIDH) in gliomas, and this mutant enzyme produces the oncometabolite 2-hydroxyglutarate (2HG). 2HG promotes gliomagenesis and is implicated in epileptogenesis. Ivosidenib (IVO), a small molecu ... Full text Link to item CiteCorrecting the drug development paradigm for glioblastoma requires serial tissue sampling.
Journal Article Nat Med · October 2023 A breakthrough in drug discovery for glioblastoma requires serial collection of tissue from the central nervous system via window of opportunity trials ... Full text Link to item CiteRecent Grants
An open-label, Phase 1b study to evaluate the safety and tolerability of eflornithine plus temozolomide in patients with newly diagnosed glioblastoma
Clinical TrialPrincipal Investigator · Awarded by Orbus Therapeutics, Inc. · 2024 - 2028A Phase 1 Trial of D2C7-IT in Combination with an Fc-engineered Anti-CD40 Monoclonal Antibody (2141-V11) Administered Intratumorally via Convection-Enhanced Delivery Followed by Perilymphatic Injections of 2141-V11 and Assessment of the Tumor Monorai
Clinical TrialPrincipal Investigator · Awarded by Exvade Bioscience Inc. · 2024 - 2027Randomized Phase 2 (Ph2) clinical trial of Lerapolturev (previously known as PVSRIPO) in recurrent glioblastoma (rGBM)
Clinical TrialCo-Principal Investigator · Awarded by Brain Tumor Research Charity · 2024 - 2027View All Grants
Education, Training & Certifications
University of Sherbrooke (Canada) ·
1998
M.D.